
IgA nephropathy is an autoimmune kidney illness, and complement, a element of the innate immune system, performs a job within the situation’s pathogenesis. Investigators have developed and examined a novel gene therapy that enters kidney cells and allows them to dam complement activation. The analysis will be offered at ASN Kidney Week 2024 October 23– 27.
The gene remedy, known as PS-002, makes use of a modified virus to deal with kidney cells known as podocytes. Administration of PS-002 in a mouse mannequin of IgA nephropathy diminished indicators of kidney dysfunction, lowered complement deposition, and ameliorated kidney scarring and different structural traits of kidney illness. In pigs, remedy with PS-002 resulted in elevated and extended gene expression in kidney tissues, with no questions of safety.
Our information show that concentrating on podocytes to modulate complement activation is an efficient therapeutic technique, and PS-002 paves the way in which to change into the primary gene remedy in improvement for the remedy of IgA Nephropathy. Purespring’s gene remedy platform exemplified by PS-002 demonstrates therapeutic genetic materials will be delivered with excessive effectivity to podocytes, opening up a brand new and extremely differentiated modality with the potential to deal with a broad vary of kidney ailments.”
Ambra Cappelletto, PhD, corresponding writer of Purespring Therapeutics, London
Examine: “Podocyte gene remedy allows glomerular complement modulation for IgA Nephropathy (IgAN) Therapy”
Supply: